文献速递胸部肿瘤放疗放疗物理与技术

模拟基于模型的个体化处方对超中央型肺肿瘤的潜在价值

Simulating the Potential of Model-Based Individualized Prescriptions for Ultracentral Lung Tumors.
PubMed 文献 · Adv Radiat Oncol · 2023-06-05

该研究对2008至2017年在本中心治疗的63例超中央型早期非小细胞肺癌患者进行虚拟再计划,应用已发表的正常组织并发症概率(NTCP)和肿瘤控制概率(TCP)模型,采用4种分割方案在满足临床约束及NTCP模型标准下选择TCP最高的最优计划(Planopt)。结果显示观察到的2年局部控制率为72%(95%CI 57%-88%),Planopt的TCP为87%(范围6%-93%);Planopt的RP3+ NTCP较观察到的RP3+降低近一半。

要点

  • 63例超中央型NSCLC患者虚拟再计划中,Planopt的TCP为87%(范围6%-93%),观察到的2年局部控制率为72%(95%CI 57%-88%)。
  • Planopt的RP3+ NTCP较观察到的RP3+降低近一半。
  • 39例患者Planopt的TCP>80%,14例患者Planopt的TCP<50%。

核心结论

  • 作者证明基于模型的处方可为超中央型NSCLC患者在遵守NTCP的同时获得更高TCP的潜力。
  • 基于NTCP和TCP驱动的模拟个体化治疗使预测的RP3+率较观察到的RP3+率减半。
  • 模拟还识别出因肿瘤较大或肿瘤距食管较近而无法在不违反NTCP的情况下提高TCP的患者。

研究设计与样本

  • 分析纳入2008至2017年在本中心治疗的63例超中央型NSCLC患者。
  • 在现行临床约束基础上,使用4种不同分割方案实施额外的基于NTCP模型的标准,包括3级及以上放射性肺炎(RP3+)和2级及以上食管炎。
  • 选择在不违反约束条件下产生最高TCP的缩放剂量分布(最优计划[Planopt]),并将Planopt预测与观察到的局部控制和毒性进行比较。

主要发现

  • 观察到的2年局部控制率为72%(95%CI 57%-88%),Planopt的TCP为87%(范围6%-93%)。
  • 39例患者Planopt的TCP>80%,14例患者Planopt的TCP<50%。
  • Planopt的RP3+ NTCP较患者观察到的RP3+降低近一半。
  • RP3+ NTCP是Planopt TCP<80%的最常见原因(14/24例患者),其次为2级及以上食管炎NTCP(5/24例患者),归因于肿瘤较大(>40 cc vs ≤40 cc;P=.002)或肿瘤距食管距离较短(≥5 cm vs <5 cm;P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of stereotactic body radiation therapy for ultracentral lung tumors is limited by increased toxicity. We hypothesized that using published normal tissue complication probability (NTCP) and tumor control probability (TCP) models could improve the therapeutic ratio between tumor control and toxicity. A proposed model-based approach was applied to virtually replan early-stage non-small cell lung cancer (NSCLC) tumors. METHODS AND MATERIALS: The analysis included 63 patients with ultracentral NSCLC tumors treated at our center between 2008 and 2017. Along with current clinical constraints, additional NTCP model-based criteria, including for grade 3+ radiation pneumonitis (RP3+) and grade 2+ esophagitis, were implemented using 4 different fractionation schemes. Scaled dose distributions resulting in the highest TCP without violating constraints were selected (optimal plan [Planopt]). Planopt predictions were compared with the observed local control and toxicities. RESULTS: The observed 2-year local control rate was 72% (95% CI, 57%-88%) compared with 87% (range, 6%-93%) for Planopt TCP. Thirty-nine patients had Planopt with TCP > 80%, and 14 patients had Planopt TCP < 50%. The Planopt NTCPs for RP3+ were reduced by nearly half compared with patients' observed RP3+. The RP3+ NTCP was the most frequent reason for TCP of Planopt < 80% (14/24 patients), followed by grade 2+ esophagitis NTCP (5/24 patients) due to larger tumors (>40 cc vs ≤40 cc; P = .002) or a shorter tumor to esophagus distance (≥5 cm vs <5 cm; P < .001). CONCLUSIONS: We demonstrated the potential for model-based prescriptions to yield higher TCP while respecting NTCP for patients with ultracentral NSCLC. Individualizing treatments based on NTCP- and TCP-driven simulations halved the predicted relative to the observed rates of RP3+. Our simulations also identified patients whose TCP could not be improved without violating NTCP due to larger tumors or a near tumor to esophagus proximity.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen I, Iyer A, Thor M, et al. Simulating the Potential of Model-Based Individualized Prescriptions for Ultracentral Lung Tumors. Adv Radiat Oncol. 2023. PMID: 38047220. doi:10.1016/j.adro.2023.101285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。